GEOVAX

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and therapy for advanced head and neck cancer. Additional development programs include preventive vaccines against Mpox and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, and Marburg), malaria and Zika virus, as well as therapies for various solid tumors... Our vision is to be a sustainable, profitable growth-oriented developer of therapies and vaccines against cancer and infectious diseases, recognized as a key contributor to improving options available to patients worldwide within our areas of focus. We also envision GeoVax as a preferred career-development organization to which highly innovative, competitive individuals aspire to develop careers.

Also known as: GeoVax Labs, Inc., GeoVax, Inc.

Primary location: Smyrna United States